Thymulin dosage, as reported in animal and in-vitro studies.

Before the details

Thymulin dosage, in plain terms: nobody has a human dose to give you, and this page does not invent one. What exists are research figures — how much thymulin scientists put into cells or animals, and how. In a dish, effects show at picomolar concentrations (trillionths of a mole per litre) ^[10]; in rodents, doses run from nanograms to low micrograms ^[13]. Native thymulin clears fast because it is a small peptide, so its human half-life (how long it lasts in the body) is not established ^[12]. Everything here is a study parameter, not a protocol.

Thymulin Peptide Dosage in Animal and In-Vitro Studies

Report thymulin peptide dosage only as a study finding. There is no approved human dose, and this site does not derive one from the animal figures.

The numbers span an enormous range because the systems do. In a dish, thymulin works at picomolar concentrations — a hormone-level signal. In a whole animal, researchers gave nanogram-to-microgram amounts to reach a tissue effect. Neither maps to a human protocol.

In vitro. Pituitary work used picomolar concentrations: zinc-bound thymulin stimulated ACTH release from rat anterior pituitary cells across roughly 0.5-50 pM, with a maximal effect near 10 pM ^[10]. That a few picomolar produces a measurable endocrine response is itself the point — it behaves like a hormone, not a bulk reagent. T-cell differentiation assays used in-vitro incubation concentrations on human marrow precursors ^[6] and on lymphocytes from malnourished children ^[8].

In animals. Reported research doses span nanogram-to-low-microgram amounts given intraperitoneally or intracerebroventricularly in rodents, with roughly 100 ng/kg/day subcutaneously in a rat pulmonary study. The LPS mouse anti-inflammatory work dosed thymulin daily for two weeks as a pretreatment before the inflammatory challenge ^[13] — a schedule, not a single shot, and a detail that matters when reading the result.

Gene therapy uses a vector dose, not a peptide dose. The inhaled asthma study delivered a single intratracheal dose of thymulin-expressing plasmid in nanoparticles — one administration of the gene that makes thymulin, not a measured amount of peptide ^[14]. The strategy exists precisely because the bare peptide clears fast ^[12]; expressing it locally sustains the signal.

Routes studied

Thymulin and its constructs have been delivered by several routes in research — all in animals, cells, or vectors. The route follows the question being asked: get the peptide into the bloodstream, into the brain, or into the lung.

ROUTES: intraperitoneal and subcutaneous for systemic exposure in rodents; intracerebroventricular (directly into the brain's ventricles) for the central neuroinflammatory and analgesic work; intratracheal and intramuscular for gene-therapy vectors; topical in a small human zinc-thymulin pilot; and in-vitro for the cell assays. The only human route in this record is the topical pilot — every injection route here is an animal route.

Is thymulin taken as an injection?

In research, thymulin has been delivered by injection routes — intraperitoneal, subcutaneous, intracerebroventricular — in animals ^[13][10]. A human topical zinc-thymulin pilot used a skin formulation. There is no approved human injectable product.

How is thymulin administered in research?

In animal and in-vitro studies, thymulin has been given intraperitoneally, subcutaneously, and intracerebroventricularly ^[13][10], with intratracheal and intramuscular delivery used for gene-therapy vectors ^[14][12] and a topical zinc-thymulin pilot in humans.

What doses of thymulin were used in animal studies?

Reported doses include nanogram-to-low-microgram amounts intraperitoneally or intracerebroventricularly in rodents, and roughly 100 ng/kg/day subcutaneously in a rat pulmonary study; gene-therapy work used a single vector dose ^[14]. In-vitro pituitary work used picomolar concentrations, maximal near 10 pM ^[10].

What is the dosage of thymulin peptide?

There is no established human dose. Studies report research doses in animals and cells — picomolar concentrations in vitro ^[10] and nanogram-to-low-microgram amounts in rodents ^[13]. These are study parameters, not protocols for people.

How to read a dose figure here

A research dose is a description, not an instruction. Each figure on this page answers "what did the experimenters give this model?" — never "what should a person take?" Three reasons the gap is unbridgeable from this record.

Species and route differ. A nanogram given intraperitoneally to a mouse, or picomolar added to a culture dish, does not convert to a human amount; absorption, distribution, and clearance differ animal to animal, let alone animal to human.

The active form is zinc-bound. Because thymulin is only active complexed with zinc 1:1 ^[1], a stated peptide amount is not the whole dose — the available zinc is part of it, which is one more reason figures do not transfer cleanly ^[2].

The human pharmacokinetics are blank. Without an established human half-life or clearance profile ^[12], there is no pharmacological basis on which a human regimen could even be calculated from the animal data. This site does not attempt it.

Half-life and safety

What is the half-life of thymulin?

HUMAN t1/2: NOT ESTABLISHED. As a small peptide, native thymulin has a short circulating half-life, but a precise human pharmacokinetic half-life is not well established in the public literature — one reason gene-therapy approaches were developed to sustain circulating levels rather than redose the bare peptide ^[12].

What is known about thymulin safety and side effects?

NOTE / GAP. Human safety data are sparse and dated, and several early human studies used a synthetic analog (nonathymulin) rather than native thymulin. There are no large modern human safety trials of native thymulin ^[12]. Thymulin is not FDA-approved for any use and is handled as a research peptide. This site does not characterize a human side-effect profile because the literature does not support one.

A structural caution applies to interpretation: because activity is strictly zinc-dependent, reported effects are entangled with zinc status, complicating any clean thymulin-specific safety read ^[2][5].